- Home
- BUSE vs NRIX Comparison
BUSE vs NRIX Comparison
Compare BUSE & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BUSE | NRIX |
|---|---|---|
| Founded | 1868 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BUSE | NRIX |
|---|---|---|
| Price | $30.29 | $26.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $27.17 | ★ $30.50 |
| AVG Volume (30 Days) | 757.7K | ★ 1.0M |
| Earning Date | 04-28-2026 | 04-08-2026 |
| Dividend Yield | ★ 4.04% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $719,584,000.00 | $76,987,000.00 |
| Revenue This Year | $23.84 | N/A |
| Revenue Next Year | $3.82 | $48.05 |
| P/E Ratio | $25.25 | ★ N/A |
| Revenue Growth | 55.66 | ★ 99.31 |
| 52 Week Low | $22.00 | $8.20 |
| 52 Week High | $31.70 | $28.23 |
Technical Indicators
Market Signals| Indicator | BUSE | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 59.01 |
| Support Level | $29.08 | $14.63 |
| Resistance Level | $30.50 | N/A |
| Average True Range (ATR) | 0.44 | 0.94 |
| MACD | -0.18 | -0.07 |
| Stochastic Oscillator | 25.22 | 51.76 |
Price Performance
Historical ComparisonAbout BUSE First Busey Corporation
First Busey Corporation is a financial holding company whose subsidiaries provide retail and commercial banking services, remittance processing, and offer financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech, and Wealth Management. The banking segment generates a vast majority of its revenue.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.